|
J Biol Chem, Vol. 275, Issue 20, 14865-14872, May 19, 2000
Positive and Negative Control of Multidrug Resistance by the Sit4
Protein Phosphatase in Kluyveromyces lactis*
Xin Jie
Chen §,
Bettina E.
Bauer¶,
Karl
Kuchler¶ , and
G. Desmond
Clark-Walker
From the Molecular Genetics and Evolution Group,
Research School of Biological Sciences, The Australian National
University, GPO Box 475, Canberra, ACT 2601, Australia and the
¶ Department of Molecular Genetics, University and Biocenter of
Vienna, A-1030 Vienna, Austria
 |
ABSTRACT |
The nuclear gene encoding the Sit4 protein
phosphatase was identified in the budding yeast Kluyveromyces
lactis. K. lactis cells carrying a disrupted sit4
allele are resistant to oligomycin, antimycin, ketoconazole, and
econazole but hypersensitive to paromomycin, sorbic acid, and
4-nitroquinoline-N-oxide (4-NQO). Overexpression of
SIT4 leads to an elevation in resistance to paromomycin and to lesser extent tolerance to sorbic acid, but it has no detectable effect on resistance to 4-NQO. These observations suggest that the Sit4
protein phosphatase has a broad role in modulating multidrug resistance
in K. lactis. Expression or activity of a membrane transporter specific for paromomycin and the ABC pumps responsible for
4-NQO and sorbic acid would be positively regulated by Sit4p. In
contrast, the function of a Pdr5-type transporter responsible for
ketoconazole and econazole extrusion, and probably also for efflux of
oligomycin and antimycin, is likely to be negatively regulated by the
phosphatase. Drug resistance of sit4 mutants was shown to
be mediated by ABC transporters as efflux of the anionic fluorescent
dye rhodamine 6G, a substrate for the Pdr5-type pump, is markedly
increased in sit4 mutants in an
energy-dependent and FK506-sensitive manner.
 |
INTRODUCTION |
The occurrence of multidrug resistance
(MDR)1 is one of the main
obstacles to the successful treatment of cancer. When treated with
chemotherapeutic drugs, many cancer cells develop resistance to a
variety of structurally and functionally unrelated compounds (for
review, see Ref. 1). In most cases, MDR is mediated by an increased
expression of the integral membrane multidrug transporters (reviewed in
Refs. 2-4). These membrane proteins, known as ATP-binding cassette
(ABC) transporters, function in an ATP-dependent way probably by increasing drug efflux and consequently lowering their intracellular accumulation. In a similar manner, many pathogenic microorganisms such as Candida albicans and Plasmodium
falciparum can use the ABC transporter-mediated drug efflux
mechanism to evade chemotherapy (5-8). However, despite the rapidly
growing number of ABC transporters identified in various organisms,
little is known about how activities of the drug transporters are
modulated and how aberrant regulation of the expression of ABC
transporter genes contributes to the acquisition of MDR in
vivo.
The ABC transporter-mediated drug efflux mechanism is evolutionarily
conserved and occurs in a variety of living organisms ranging from
bacteria to humans. An example is a recent work demonstrating that the
Lactococcus lactis ABC transporter LmrA is able to confer MDR in human cells (9). The recently completed genome sequencing project of Saccharomyces cerevisiae has revealed the
presence of as many as 29 proteins belonging to the ubiquitous ABC
superfamily (10) that transport a wide range of chemical compounds (11, 12). The yeast ABC proteins so far characterized, such as Pdr5, Snq2,
Ycf1 and Yor1, confer MDR with physiological and biochemical properties
very similar to the human MDR1-encoded P-glycoprotein (P-gp)
and to Mrp1, which is known as a multidrug resistance associated protein (13-22). Functional similarities between yeast and human ABC
transporters have also been supported by a number of studies showing
that expression of human P-gp and Mrp1 confers drug resistance in yeast
(23-27).
Extensive efforts have been directed to understanding the regulation of
ABC transporter activity at both the transcriptional and
post-translational levels. Three transcriptional activators of the
Cys6 zinc finger type have been genetically identified in
S. cerevisiae (28-32). The Pdr1 and Pdr3 proteins control
the transcriptional levels of PDR5, SNQ2, YOR1,
PDR10, and PDR15 by direct binding to DNA in the
promoter of the target genes (33-37). The Yrr1 protein is involved in
the regulation of SNQ2 (29). However, the mechanism of the
regulatory pathway upstream of PDR1, PDR3, and
YRR1 remains elusive. Two recent studies have revealed a
functional link of the Pdr1 and Pdr3 transcriptional factors to the
yeast homologues of the stress-dependent transcriptional factor AP1 and the heat shock protein Hsp70 (38, 39). These observations suggest the presence of a signaling pathway upstream of
Pdr1 and Pdr3 in the cellular response to drug stress.
At a post-translational level, attention has been directed to a
possible role of protein phosphorylation/dephosphorylation in the
modulation of ABC transporter activity. Because the human P-gp is
phosphorylated in vivo, an approach is to develop
chemosensitizers that inhibit P-gp function at the level of
phosphorylation and reverse the MDR phenotype in tumor cells. Early
studies have demonstrated that a change in the state of phosphorylation
of P-gp has been associated with differences in relative drug
resistance of mammalian cells, suggesting that the
phosphorylation/dephosphorylation mechanisms may be involved in the
regulation of the efflux activity of the drug transporter (40, 41).
More recently, similar results were obtained with the human Mrp1
transporter. By using protein kinase inhibitors, it has been shown that
phosphorylation of the serine residues of Mrp1, probably by protein
kinase C, plays an important role in modulating drug accumulation in
resistant cells (42, 43). Biochemical and genetic studies identified
four serine residues in a basic domain of the linker region of the human P-gp that are accessible and recognized as major targets for
phosphorylation by protein kinase C or protein kinase A. However, recent mutational analysis showed that a mutant P-gp, with the putative
phosphorylation sites for protein kinase C within the linker region
changed to non-phosphorylatable alanine residues, or to aspartic acid
residues to mimic permanently dephosphorylated serine residues, is
still functionally active to diminish drug accumulation within cells
(44, 45). This suggests that phosphorylation by protein kinase C may
not play a role in regulating drug transport of P-gp. Whether the
phosphorylation of an acidic domain of the linker region is involved in
the modulation of drug transport activity remains to be established
(46). By contrast, in S. cerevisiae, a phosphorylation site
has been proposed in the Ycf1 protein (21), an orthologue of the human
Mrp1 transporter located on vacuolar membrane (18, 19, 21). With Ycf1,
substitution of a serine to alanine residue in the potential protein
kinase A phosphorylation site in a central region of Ycf1 renders the protein non-functional.
In this study we identified nuclear mutations conferring MDR in the
budding yeast Kluyveromyces lactis. We find that the gene defined by the mutations encodes a protein phosphatase belonging to the
Sit4/PPV/PP6 family. It was found that the Sit4 protein has a broad
role in regulating MDR by altering the expression or activity of
different membrane drug transporters. To our knowledge this is the
first protein phosphatase genetically identified that is involved in
modulation of multidrug resistance.
 |
EXPERIMENTAL PROCEDURES |
Strains and Media--
Table I
lists the yeast strains used in this study. Complete medium (GYP)
contains 0.5% Bacto-yeast extract, 1% Bacto-peptone, and 2% glucose.
Glycerol medium (GlyYP) contains 2% glycerol in place of glucose.
Glucose minimal medium (GMM) contains 0.17% Difco yeast nitrogen base
without amino acids and ammonium sulfate, 0.5% ammonium sulfate, and
2% glucose. Nutrients essential for auxotrophic strains were added at
25 µg/ml for bases and 50 µg/ml for amino acids. ME medium used for
sporulation of K. lactis contains 5% malt extract and 2%
Bacto-agar.
Resistance to antimycin A, oligomycin, and paromomycin was tested on
GlyYP plates. Resistance to ketoconazole and
4-nitroquinoline-N-oxide (4-NQO) was tested on GMM plates
supplemented with appropriate amino acids to meet auxotrophic
requirements. Resistance to econazole was tested on GYP. For testing
sensitivity to sorbic acid, the GYP medium was adjusted to pH 4.5 according to Piper and co-workers (47). The drugs antimycin A,
oligomycin, econazole, and rhodamine 6G used in this study were all
purchased from Sigma and dissolved in ethanol. Paromomycin
(Parke-Davis) was dissolved in sterile water. 4-NQO (Sigma) was
dissolved in acetone, whereas the stock solution for ketoconazole (ICN
Pharmaceuticals) was prepared with Me2SO.
Manipulation of K. lactis--
Transformation of K. lactis was performed by the lithium acetate/dimethyl sulfoxide
method (48) as described in detail (49). Genomic DNA was extracted from
protoplasts obtained by Zymolyase treatment (50). Sporulation of
K. lactis diploid strains was induced on ME agar for 2-3
days. Tetrad analysis was performed using a de Fonbrune
micromanipulator following treatment of asci with Zymolyase 20T (0.7 mg/ml in 1 M sorbitol, Seikaguku Co., Tokyo, Japan) for 10 min at 30 °C. Spores were germinated at 28 °C for 2-3 days on
GYP medium.
Isolation of K. lactis Oligomycin-resistant Strains--
To
obtain oligomycin-resistant mutants, strain PM6-7A was grown overnight
in liquid GYP medium, and approximately 6 × 106 cells
were spread on GlyYP plates containing 1.0 µg/ml oligomycin. After 1 week at 28 °C papillae were transferred to oligomycin-GlyYP plates.
Oligomycin-resistant clones were then grown in liquid GYP for 48 h
before being streaked onto drug-free GYP plates. After 2 days at
28 °C colonies were replica-plated onto oligomycin-GlyYP plates to
examine the stability of the oligomycin-resistant phenotype. Stable
oligomycin-resistant clones were retained for further analysis.
Nucleic Acid Manipulations--
Standard techniques were used
for generating recombinant DNAs and performing DNA blot hybridizations
as described by Sambrook et al. (51). The integrative
plasmid pURA-oli was constructed by the insertion of a 1.8-kb
HindIII-SalI fragment, containing the K. lactis SIT4 gene, into the HindIII and SalI
sites of the URA3-based integrative vector pUC-URA3/4 (52).
The same fragment was cloned into the HindIII and
SalI sites of the K. lactis vector pUK-S11 (52)
to produce pUK-oli. The 3.1-kb KpnI-SalI fragment containing KlSIT4 was cloned into the KpnI and
SalI sites of the K. lactis overexpression vector
pCXJ3 (53), the K. lactis/S. cerevisiae multicopy
vector pCXJ15,2 and the
S. cerevisiae centromeric vector pFL39 (54), to produce pCXJ3-KlSIT4, pCXJ15-KlSIT4, and pFL39-KlSIT4. To construct
pCXJ22-ScSIT4, a 1.98-kb SacII-PvuII fragment,
containing the S. cerevisiae SIT4 (kindly provided by K. Arndt), was blunt-ended with T4 DNA polymerase and ligated
to the SmaI-digested S. cerevisiae/K. lactis
shuttle vector pCXJ22 (53). A 1.98-kb
HindIII-EcoRI fragment containing ScSIT4 was cloned into the HindIII and
EcoRI sites of pCXJ15 to produce pCXJ15-ScSIT4.
Cloning and Sequencing of KlSIT4--
The K. lactis
sit4-1 mutant CW2-8B was transformed with a K. lactis
partial Sau3AI genomic library cloned in the K. lactis/Escherichia coli shuttle vector KEp6 (55). The vector
contains the S. cerevisiae URA3 gene, which upon
transformation, complements the uraA1 defect of K. lactis. Approximately 8,300 Ura+ transformants were
scored and replica-plated onto GlyYP. After incubation at 37 °C for
2 days, 11 Gly+ colonies were obtained. Further analysis
confirmed that all 11 clones show co-segregation of the
Ura+ and the Gly+ phenotypes at 37 °C after
growth in non-selective medium. Total DNA was extracted from the
transformants, and plasmids were rescued into E. coli.
Restriction enzyme analysis showed that the 11 plasmids are identical
and derived from a single chromosomal locus. A physical map was
established from one of the complementing plasmids, pOli2/1, which
contains an insert of 7.05 kb (Fig. 2A). Subcloning of
KlSIT4 was performed as follows. The plasmid pOli2/1 was
digested by BamHI, EcoRI, HindIII,
KpnI, and SalI plus XhoI,
respectively, followed by self-ligation that created a series of
internal deletions in the insert DNA of pOli2/1. The resulting plasmids
were re-introduced into CW2-8B by transformation and examined for
complementation of the sit4-1 mutation on GlyYP at 37 °C.
This enabled us to localize the KlSIT4 gene on a 1.8-kb
HindIII-SalI fragment on the right end of the
insert DNA as shown in Fig. 2A. The nucleotide sequence of
KlSIT4 was determined by the dideoxy chain termination
method (56) after subcloning the 1.8-kb DNA fragments into pTZ18U and 19U (Amersham Pharmacia Biotech). Templates for sequencing were obtained by using DNase I to create a series of nested deletions from
the ends of yeast DNA insert. The deduced protein sequence was compared
with sequences in the Swiss-Prot data bases.
Disruption of KlSIT4--
The 1.8-kb
HindIII-SalI fragment containing
KlSIT4 was cloned into pTZ18U to produce pTZ18-oli. The
plasmid pTZ18-oli was digested with BclI that creates an
internal deletion within the SIT4 coding region (Fig.
2A). A 1.05-kb BglII fragment containing the
URA3 gene of S. cerevisiae was then inserted to
produce pKlsit4::URA3/1. Disruption of the chromosomal
SIT4 gene was achieved by one-step gene replacement (57)
with a 2.05-kb EcoRI-HindIII fragment containing
the disrupted gene isolated from pKlsit4::URA3/1. Following transformation of the haploid strain PM6-7A, Ura+ colonies
were screened and tested for stability of uracil independence after
growth on non-selective medium. Genomic DNA from stable strains was
examined for disruption of the resident gene by Southern blot analysis.
ATPase Activity Determination--
Preparation of K. lactis mitochondrial extracts has been described in a previous
paper (58). The mitochondrial ATPase activity assay was performed
essentially according to Law et al. (59).
Flow Cytometry of Yeast Cells--
K. lactis strains
were grown in complete medium to an A600 of
about 1.0. For steady state rhodamine 6G accumulation assays, rhodamine
6G was added to a final concentration of 5 µM, and
dye-loading was allowed for 60 min at 30 °C. Rhodamine 6G efflux was
stopped by a 1:10 dilution of the cells in ice-cold water. For the
measurement of dye efflux, cells were washed, resuspended in
phosphate-buffered saline (PBS) containing 10 mM sodium
azide, and loaded with rhodamine 6G (5 µM final
concentration) for 60 min at 30 °C, with or without a 30-min
preincubation with the inhibitor FK506 (10 µM final
concentration). After dye-loading, cells were harvested, washed, and
resuspended in prewarmed PBS containing 1% glucose to initiate
rhodamine 6G efflux. Efflux was allowed for 15 min at 30 °C and then
stopped by dilution of the cells in ice-cold water. Intracellular
rhodamine fluorescence was analyzed with a FACSCalibur flow cytometer
(Becton Dickinson Medical Systems) using Cell Quest software.
 |
RESULTS |
Identification of K. lactis Nuclear Mutations Conferring Oligomycin
Resistance--
In the course of our studies on the K. lactis mitochondrial F1-ATPase that is involved in the
maintenance of mitochondrial genome integrity (58, 60, 61), we sought
K. lactis mutants resistant to the antibiotic oligomycin.
This screening procedure was based on observations that the majority of
oligomycin-resistant mutants in S. cerevisiae and K. lactis occur in the mitochondrial DNA-encoded subunits 6 and 9 of
the ATP synthase F0 complex (62-65). By this means we
hoped to examine whether any structural and functional alterations in
the F0 subunits would affect the integrity of the mitochondrial genome. From these studies we have identified two mutants
that are resistant to oligomycin due to a mutation in a nuclear gene.
K. lactis strains PM6-7A/oli4 and PM6-7A/oli18 are resistant
to 1.0 µg/ml oligomycin on GlyYP medium compared with the wild-type parent PM6-7A whose growth is completely inhibited by the drug (Fig.
1). PM6-7A/oli4 was crossed to the
wild-type strain CK56-16C to produce the diploid CW2. Sporulation and
analysis of 19 tetrads from CW2 showed that the oligomycin-resistant
trait segregated (2R):(2S) in all tetrads,
indicating that the drug resistance was conferred by a single nuclear
allele rather than by mutations in mtDNA-encoded genes. Because the
mutation can be complemented by the cloned SIT4 gene (see
below), we designated the allele from the isolate PM6-7A/oli4 as
sit4-1. As a sit4-1/SIT4 diploid strain is oligomycin-sensitive, the sit4-1 allele is thus
recessive. The mutation in the second isolate, PM6-7A/oli18, is likely
to be allelic to sit4 as the mutant phenotype can be
complemented by SIT4 (data not shown). This allele has been
designated sit4-2.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 1.
Growth and multidrug-resistant phenotypes of
K. lactis sit4 mutants. Strains PM6-7A (wild-type
(WT)), CW2-8B (sit4-1), PM6-7A/oli
(sit4-2), and CK254/1 (sit4 ::URA3)
were diluted to 5 × 104 cells/ml, and 10-µl
aliquots were applied to GlyYP, GlyYP supplemented with oligomycin
(Oli) and antimycin (Ant) at a concentration of 1 µg/ml and 0.2 µM, GMM supplemented with ketoconazole
(Keto) at 4 µg/ml, and GYP supplemented with econazole
(Eco) at 0.5 µg/ml. The GlyYP plates were incubated at
30 °C for 4 days, 37 °C for 5 days, and 19 °C for 7 days. The
plates containing the drugs were incubated at 28 °C for 4-5 days
before being photographed.
|
|
To see whether resistance to oligomycin is related to any structural
and functional alterations in the mitochondrial
F1F0-ATP synthase as a result of
sit4 mutations, ATPase activity was measured in isolated
mitochondria. We found that the sit4-1 strain CW2-8B and the
sit4 null mutant CK254/1 (see below) retain a high
mitochondrial ATPase activity that is as sensitive as in wild-type
cells to oligomycin inhibition (data not shown). The sensitivity of the ATP synthase to oligomycin in the mutants suggests that the drug resistance observed is not due to alterations in the biochemical properties of F1F0-ATP synthase. Rather, it
raises the possibility that SIT4 controls the function of a
membrane transporter that affects accumulation of oligomycin within cells.
sit4 Mutants Are Defective in Respiration-dependent
Growth--
Although sit4 mutants can grow on glycerol
medium with or without supplementation of oligomycin, a defect in the
respiration-dependent growth is noticeable on GlyYP.
Compared with the wild-type strain PM6-7A, the mutants have a
significantly slower growth after incubation for 2 days at 30 °C
(not illustrated). Moreover, growth on GlyYP can be completely
inhibited when cells are incubated at 37 or 19 °C (Fig. 1). The
temperature- and cold-sensitive respiratory-deficient phenotype was
also observed when cells were grown on plates containing 2% ethanol in
place of glycerol.
Cloning of KlSIT4--
The temperature-sensitive respiratory
growth of sit4 mutants has allowed us to isolate
KlSIT4 by complementation on glycerol medium. After
transformation of CW2-8B with a K. lactis genomic DNA
library, transformants were screened for the ability to grow on GlyYP
at 37 °C. Plasmids were rescued from the Gly+ clones,
and physical maps were established. All the plasmids from 11 independent transformants contained the same chromosomal locus with an
insert size of 7.05 kb. The physical map of the plasmid pOli2/1 is
shown in Fig. 2A. When a
1.8-kb HindIII-SalI fragment is subcloned into
the K. lactis vector pUK-S11, the resulting plasmid,
pUK-oli, was found to complement the Gly phenotype of the
sit4-1 mutant CW2-8B and the sit4-2 strain
PM6-7A/oli18.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 2.
Physical map of the K. lactis
chromosomal region containing the SIT4 gene and
Southern blot hybridization confirming the disruption of
SIT4. A, restriction map of
chromosomal region flanking SIT4. Also shown is the strategy
used for SIT4 gene disruption by deletion of a
BclI fragment in the SIT4 coding sequence and
insertion of the S. cerevisiae URA3 gene. The
arrow indicates the position and orientation of the
SIT4 open reading frame. The nucleotide sequence of
KlSIT4 has been assigned GenBankTM/EBI accession
number X87624. The starred SalI site is from the
vector KEp6. B, Southern blot hybridization; total DNA from
the disruptant CK254/1 (lane 2) and its parental strain
PM6-7A (lane 1) was digested with HindIII and
EcoRI and hybridized with the 32P-labeled
1.25-kb HindIII-EcoRI fragment containing
SIT4 coding sequence. The hybridization signals are
indicated as a band of 2.05 kb in the disruptant and 1.25 kb in the
control. A faint band of 2.35 kb may represent cross-hybridization to
sequences of type 2A protein phosphatases.
|
|
Confirmation that the cloned DNA fragment contains the same locus as
the one defined by the sit4 mutations was performed first by
cloning the 1.8-kb HindIII-SalI fragment into the
integrative vector pUC-URA3/4 carrying the S. cerevisiae
URA3 gene. The resulting plasmid, pURA-oli, was targeted to the
chromosomal sit4-1 locus of CW2-8B after digestion with
ClaI which cuts within the SIT4 coding sequence.
The transformant, CK231, grew on GlyYP at 37 °C. This implies that
this segment of DNA has single copy-complementing activity and is
thereby unlikely to be a multicopy suppressor of sit4-1.
Second, pURA-oli was targeted onto the chromosomal SIT4
locus of the wild-type strain PM6-7A (uraA1). Two
independent transformants, CK230/3 and CK230/4, were crossed to the
CW2-8B (sit4-1 and uraA1), and the resulting
diploids, CK233 and CK234, were sporulated and dissected for tetrad
analysis. The Ura+ and OliR phenotypes
segregated 2+:2 in a total of 28 tetrads
analyzed. Moreover, OliR co-segregated with
Ura . These results suggest that the cloned DNA fragment
is allelic to sit4-1. Additional evidence supporting this
view is the observation that a disrupted allele of the SIT4
gene has the same phenotypes as sit4-1 and sit4-2
(see below).
Nucleotide sequence analysis of the 1.8-kb
HindIII-SalI DNA fragment revealed the presence
of a 927-bp open reading frame capable of encoding a protein of 309 amino acids with a predicted molecular mass of 35,285 daltons.
Comparison of the deduced protein with sequences in the Swiss-Prot data
bases revealed that it has high homology to a large group of
serine/threonine protein phosphatases from various sources. The protein
showing the highest level of homology is the gene product of the
S. cerevisiae SIT4 gene (66) which shares 92.9% identical
residues (not illustrated). The Sit4 protein together with its
homologues, Ppe1 protein of the fission yeast Schizosaccharomyces
pombe (67-69), PPV of Drosophila melanogaster (70),
and the human PP6 enzyme (71), have been thought to be the catalytic
subunit of a type 2A-related serine/threonine protein phosphatase. The
proteins Ppe1, PPV, and PP6 have 70.2, 62.7, and 62.3% residues
identical to the K. lactis protein. Phylogenetic tree
analysis also indicates that the cloned gene most likely belongs to the
Sit4/PPE1/PPV group of
phosphatases.3 By analogy to
S. cerevisiae, the gene is termed KlSIT4.
KlSIT4 Is Not Essential for Cell Viability--
The chromosomal
SIT4 gene was disrupted by replacing a 306-bp
BclI fragment within the coding region by the
URA3 gene in the K. lactis haploid PM6-7A (Fig.
2A). Correct disruption of the gene was confirmed by
comparing genomic Southern blots of the disruptant CK254/1 and PM6-7A
(Fig. 2B). Digestion with the restriction enzymes
EcoRI and HindIII, followed by hybridization with
a 32P-labeled 1.25-kb EcoRI-HindIII
fragment containing the SIT4-coding sequence, yielded bands
of 2.05 kb for CK254/1 and 1.25 kb for PM6-7A. This is the expected
result for a SIT4-disrupted allele with an internal deletion
within the SIT4 gene and replacement by the insertion of
URA3. The successful disruption of SIT4 indicates that the gene is not essential in K. lactis strains with the
PM6-7A background.
The sit4 null mutant, CK254/1, displayed the same phenotypes
as sit4 alleles. These include 1) a slightly slower growth
on GYP compared with the parental strain PM6-7A (not illustrated), 2)
resistance to oligomycin on GlyYP (Fig. 1), and 3) a
respiratory-deficient phenotype on glycerol at 37 and 19 °C (Fig.
1). Because sit4-1 and -2 alleles confer similar phenotypes
as the null mutant, they probably cause loss of Sit4 function.
Complementation between KlSIT4 and ScSIT4--
The S. cerevisiae strain CY144 carries the sit4-102 allele
which is temperature-sensitive for growth on GYP (72). CY144 was
transformed with the plasmid pFL39-KlSIT4, and the transformants were
examined for growth at 37 °C. sit4-102 cells carrying the K. lactis gene can grow at the restrictive temperature (Fig.
3A), indicating that
KlSIT4 can functionally complement the sit4
mutation of S. cerevisiae. Reciprocally, the
temperature-sensitive phenotype of K. lactis sit4-1 on
glycerol medium can be complemented by ScSIT4 when the
plasmid pCXJ22-ScSIT4 was introduced into the K. lactis
sit4-1 mutant CW2-8B (Fig. 3B). Functional
inter-complementation between KlSIT4 and ScSIT4
was further supported by the experiments showing that ScSIT4
can complement the paromomycin- and sorbic acid-hypersensitive
phenotype of K. lactis sit4 mutants (see below).

View larger version (58K):
[in this window]
[in a new window]
|
Fig. 3.
Complementation between KlSIT4
and ScSIT4. A, the S. cerevisiae sit4-102 mutant CY144 was transformed with the plasmid
pFL39-KlSIT4 which carries KlSIT4. The Trp+
transformants (right patch) and the host strain CY144
(left patch) were streaked onto GYP medium and incubated for
5 days at 37 °C. B, the K. lactis sit4-1
mutant CW2-8B was transformed with pCXJ22-ScSIT4 carrying
ScSIT4. Ura+ transformants and the parental
strain CW2-8B were streaked onto GlyYP medium and incubated for 3 days
at 37 °C before being photographed.
|
|
K. lactis sit4 Mutants Have a Typical MDR Phenotype--
The
observation that resistance of K. lactis sit4 mutants to
oligomycin is not due to functional modification of the
F1F0-ATP synthase (see above) suggested a role
for KlSIT4 in the control of drug transport activities.
Resistance to oligomycin could be a consequence of decreased drug
accumulation within cells mediated by increased activity of membrane
drug pumps. Consequently it was decided to ascertain whether K. lactis sit4 mutants have an altered sensitivity to drugs that are
structurally unrelated to oligomycin.
On GlyYP medium supplemented with erythromycin, tetracycline,
chloramphenicol, or carbonyl cyanide
m-chlorophenylhydrazone, and GYP medium plus cryptopleurine,
the strains CK254/1 (sit4 ::URA3) and CW2-8B
(sit4-1) did not show an increased or decreased level of
resistance compared with the wild-type strain PM6-7A (not illustrated). However, the sit4 mutants showed a significantly elevated
level of resistance to antimycin A and the antifungal drugs
ketoconazole and econazole (Fig. 1). At the concentrations of 0.2 µM for antimycin A on GlyYP medium, the wild-type strain
PM6-7A failed to grow, whereas the drug does not inhibit the growth of
the sit4 mutants. The sit4-1 mutant CW2-8B seems
to have a higher resistance level to antimycin compared with the
sit4-2 strain PM6-7A/oli18. Likewise, the sit4
mutants are resistant to ketoconazole and econazole at a concentration
as high as 4.0 and 0.5 µg/ml, respectively, whereas growth of the
wild-type PM6-7A is clearly inhibited by these drugs at the same
concentrations (Fig. 1). As antimycin and the antifungal drugs have
cellular targets different from oligomycin, these experiments demonstrate that mutation in SIT4 leads to a typical MDR in
K. lactis.
Expression of SIT4 Is Required for Resistance to Paromomycin,
Sorbic Acid, and 4-NQO--
In contrast to the negative control of
resistance to oligomycin, antimycin, ketoconazole, and econazole, it
has been found that Sit4p has a positive control over tolerance to
other drugs. As can be seen in Fig. 4,
K. lactis strains containing the sit4-1 or the
sit4 ::URA3 alleles are hypersensitive to
paromomycin on GlyYP. The wild-type strain, PM6-7A, is able to tolerate
paromomycin at a concentration of 0.1 mg/ml, whereas growth of the
sit4-1 mutant CW2-8B and the sit4 null mutant
CK254/1 is completely inhibited by the drug at 0.05 mg/ml. These
results imply that SIT4 is required for paromomycin
resistance under normal physiological conditions. Resistance to
paromomycin can be restored to the wild-type level when the plasmid
pCXJ22-ScSIT4, carrying ScSIT4, is introduced into the
K. lactis sit4 mutant (not illustrated).

View larger version (45K):
[in this window]
[in a new window]
|
Fig. 4.
Hypersensitivity of K. lactis sit4
mutants to paromomycin, sorbic acid, and 4-NQO and
hyper-resistance of SIT4-overexpressing cells to
paromomycin. K. lactis cells were grown in liquid
minimal medium to stationary phase, diluted to 5 × 104 cells/ml, and 10-µl aliquots were applied to GlyYP,
GlyYP supplemented with various concentrations of paromomycin, GYP
supplemented with the indicated concentration of sorbic acid at pH 4.5, and GMM supplemented with 4-NQO. Photos were taken after incubation at
28 °C for 4 days.
|
|
The above results suggest that the Sit4 protein phosphatase positively
regulates drug transporter(s) specific for paromomycin. The
dephosphorylating activity of the enzyme may directly or indirectly activate the function of membrane drug transporters. Consistent with
this view is the observation that a further increase of Sit4 activity
by overexpression of KlSIT4 leads to a drastic elevation in
resistance to paromomycin (Fig. 4). Wild-type cells are unable to grow
on GlyYP supplemented with paromomycin at a concentration higher than
0.2 mg/ml, whereas the wild-type strain, PM6-7A, overexpressing KlSIT4 on the multicopy plasmid pCXJ3-KlSIT4 can resist
paromomycin at a concentration as high as 2.0 mg/ml (not illustrated).
To determine whether overexpression of ScSIT4 also confers
high level resistance to paromomycin in K. lactis, PM6-7A
was transformed with the K. lactis multicopy plasmid
pCXJ22-ScSIT4 bearing ScSIT4. On GlyYP medium supplemented
with 0.1 mg/ml of paromomycin, the transformants show an improved
growth compared with the control strain PM6-7A (Fig. 4). However, the
transformants do not tolerate the drug at a concentration beyond 0.2 mg/ml. The data indicate that ScSIT4 can only partially
replace KlSIT4 for resistance to paromomycin at high concentration.
In addition to paromomycin, it has also been found that K. lactis
sit4 mutants are hypersensitive to sorbic acid and the mutagen 4-NQO. Both CW2-8B (sit4-1) and the sit4 null
mutant CK254/1 are sensitive to inhibition by sorbic acid at 0.5 mM on GYP medium adjusted to pH 4.5 and by 4-NQO at 0.5 µg/ml on GMM, whereas the wild-type strain PM6-7A can grow under the
same conditions (Fig. 4). Unlike the case for paromomycin,
overexpression of both KlSIT4 and ScSIT4 can only
slightly increase tolerance to sorbic acid as estimated by colony size
of the strains on plates containing the drugs. PM6-7A overexpressing
the SIT4 strain alleles are unable to grow when the sorbic
acid concentration is increased to 1 mM (not illustrated).
By the same criterion, K. lactis cells overexpressing either
KlSIT4 or ScSIT4 do not have a detectable
resistance to 4-NQO higher than the parental strain PM6-7A. On GMM
plates containing 4-NQO at 1.0 µg/ml, both PM6-7A and its
transformants carrying the SIT4 overexpression plasmids fail
to form colonies (not illustrated).
Mutations in SIT4 Increase Efflux of Rhodamine 6G--
Resistance
to the antifungal drugs ketoconazole and
econazole4 has been shown to
be mediated by the Pdr5 transporter in the yeasts S. cerevisiae and C. albicans (8, 73). The resistance of
K. lactis sit4 mutants to these two drugs suggests that the activity of a Pdr5-type ABC transporter might be increased in the
mutant cells. To test this hypothesis, accumulation of the anionic
fluorescent dye rhodamine 6G in the cells was measured by flow
cytometry. Previous studies have established that efflux of rhodamine
6G is mediated by Pdr5 in S. cerevisiae (12). If mutations
in SIT4 affect the function of a putative Pdr5 pump in
K. lactis, it would be reflected by increased drug efflux
activity in the mutants.
To address the above question, it is necessary to confirm that K. lactis, like S. cerevisiae, indeed has an active
rhodamine 6G efflux system mediated by a Pdr5-type ABC transporter.
When fluorescence intensity in energy-deprived and dye-preloaded cells was measured (Fig. 5), the
energy-deprived wild-type PM6-7A strain has a strong accumulation of
rhodamine 6G within cells. Following re-energization by glucose, the
relative fluorescence intensity is decreased by 4.6-fold. The strong
dye efflux activity in the re-energized cells can be largely reversed
by addition of the Pdr5-specific inhibitor FK506 (73, 74). The energy
dependence and FK506 sensitivity strongly indicate the involvement of a
Pdr5-like ABC transporter responsible for efflux of rhodamine 6G in
K. lactis.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 5.
Energy-dependent and
FK506-sensitive rhodamine 6G efflux from PM6-7A (wild-type) and CK254/1
(sit4 ::URA3). The intracellular
fluorescence after an effluxing period of 15 min at 30 °C was
measured by flow cytometry in dye-preloaded, energy-depleted
( glu), and energized (+glu) cells in the
presence or absence of FK506.
|
|
A possible difference in rhodamine 6G efflux activity between the
wild-type PM6-7A and its isogenic sit4 mutant CK254/1 was examined. When steady state levels of cellular fluorescence were measured after dye loading for 1 h at 30 °C, it was observed
that accumulation of rhodamine 6G is significantly higher in PM6-7A compared with CK254/1 (Fig. 6). The mean
fluorescence intensity in the sit4 mutant is only 31% of
the wild-type strain. These results indicate that mutation in
SIT4 increases the efflux of rhodamine 6G. The difference in
rhodamine 6G efflux activity between PM6-7A and CK254/1 is even more
pronounced when cells are energized by glucose (Fig. 5). Under
energized conditions, the sit4 mutant (CK254/1 + glu) has
very low cellular accumulation of fluorescence which is only 7.6% of
the wild-type (PM6-7A + Glu). Furthermore, the strong dye efflux
activity of the energized CK254/1 cells can be inhibited to some extent
by addition of FK506. This observation strongly supports the idea that
the accelerated rhodamine 6G efflux in sit4 strains is
mediated by a Pdr5-type ABC transporter.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 6.
Flow cytometry analysis showing steady state
fluorescence intensities in the K. lactis sit4 mutant
CK254/1 (lower panel) compared with its isogenic
parent PM6-7A (upper panel). The rhodamine 6G
accumulation in steady state cells was measured after a dye-loading for
60 min at 30 °C. The mean fluorescence intensities of the strains
are indicated.
|
|
 |
DISCUSSION |
The Sit4 protein is a type 2A-related protein phosphatase (75)
that has been originally identified in S. cerevisiae.
Specific mutations in the ScSIT4 gene restore transcription
of the HIS4 gene in the absence of the
trans-acting DNA binding factors GCN4, BAS1, and BAS2 that
are normally required for HIS4 expression (66). Loss of the
SIT4 gene product was proposed to cause aberrant transcriptional activity of the RNA polymerase II because of
accumulation of the phosphorylated form of an unknown transcription
factor. Subsequent studies have shown that the Sit4 protein phosphatase is involved in cell cycle progression and bud formation (72, 76), in
control of glycogen synthase and phosphorylase activities (77), and in
the ceramide-induced and Tor-signaling pathways (78-80). The Sit4
function is evolutionarily conserved as S. cerevisiae sit4
mutants can be complemented by the SIT4 homologues from
D. melanogaster and human cells (70, 71).
Reported in this study is the isolation of a SIT4 homologue
from the budding yeast K. lactis. Several novel functional
aspects of the Sit4 protein phosphatase in K. lactis are
described. First, K. lactis SIT4 is not essential as
disruption of the gene in several strains did not cause non-viability.
In S. cerevisiae, null mutants are viable only in a genetic
background with the SSD-v1 version of the polymorphic
SSD1 gene (72). Second, K. lactis sit4 mutants are clearly impaired in respiratory function. Respiratory growth of
sit4 mutants can be totally abolished when cells are grown at 37 or 19 °C. Although a growth defect on non-fermentable carbon sources was observed in the S. cerevisiae transcriptional
suppressor sit4 mutants (66), a SIT4-disrupted
strain with a SSD1-v1 background is respiratory-competent
(72). Third, we find that sit4 mutants of K. lactis have an increased formation of specific nuclear mutations on exposure to ethidium bromide that permits the recovery of cells lacking mitochondrial DNA, suggesting that Sit4p may affect
susceptibility to a mutagenic agent such as ethidium
bromide.5 Finally, Sit4p has
an important role in regulating MDR.
In S. cerevisiae, two classes of multidrug resistance genes
have been genetically identified. The first class of genes are ones
encoding membrane ATP-binding cassette (ABC) transporters such as
PDR5/STS1/YDR1, SNQ2, YCF1, YOR1, and
PDR12 that mediate drug efflux out of cells (13-22, 47).
The second class of genes are those acting as transcriptional
activators for the ABC transporter genes. Among the well characterized
transcriptional regulators are PDR1 and PDR3,
which control the transcriptional levels of PDR5,
YOR1, PDR10, and PDR15 (28, 30, 35,
37, 81). Thus, the simplest interpretation for the MDR phenotype
associated with K. lactis sit4 mutants is that the Sit4
protein phosphatase has a regulatory role on either of the two types of
genes mentioned above, which ultimately modify the drug efflux capacity
of the membrane ABC transporters.
K. lactis sit4 mutants display altered sensitivity to a wide
range of mechanistically unrelated drugs. These drugs include the
mitochondrial inhibitors oligomycin, antimycin A, and paromomycin that
target to the ATP synthase, the bc1 complex of
the respiratory chain, and mitochondrial ribosomes, respectively, the
antifungal drugs ketoconazole and econazole, the antimicrobial
preservative sorbic acid, and the mutagen 4-NQO. Efflux of most of
these compounds has been shown to require specific ABC transporters in
yeast. In S. cerevisiae, efflux of the antifungal drugs
ketoconazole and econazole4 is mediated by the Pdr5
transporter (8, 73); oligomycin is transported by Yor1 (17); the
detoxification of sorbic acid requires the Pdr12 pump (47), whereas
4-NQO is a specific substrate for the ABC protein Snq2 (20).
Transporters for antimycin A and paromomycin have not yet been assigned.
In K. lactis sit4 mutants, at least four distinct types of
transporters appear to be affected. Recent studies have revealed that a
single pump is responsible for transport of ketoconazole, econazole,
oligomycin, and antimycin.2 This transporter, most likely
corresponding to the Pdr5 homologue in K. lactis, is
negatively regulated by Sit4p. Rhodamine 6G could also be transported
by the same protein. In contrast, a membrane transporter, responsible
for detoxification of paromomycin, is positively regulated by Sit4p.
sit4 mutants are hypersensitive to paromomycin, and
overexpression of SIT4 causes a drastic elevation of
resistance to the antibiotic. In addition, two other transporters, required for resistance to sorbic acid and 4-NQO, are also positively regulated by Sit4p. Based on the differential responses to
overexpression of SIT4, these two transporters, together
with that for paromomycin, are functionally distinct. In contrast to
the paromomycin transporter, the function of the pump for sorbic acid
is only slightly augmented in cells overexpressing SIT4,
whereas the detoxifying capacity of the pump for 4-NQO is not affected
by increasing SIT4 dosage. By analogy to S. cerevisiae, the pumps responsible for sorbic acid and 4-NQO might
be related to the Pdr12 and Snq2 transporters of S. cerevisiae (20, 47).
Strong support for a role of Sit4p in modulating MDR by altering the
function of membrane transporters and ultimately the intracellular drug
accumulation comes from the drug efflux assay using the fluorescent dye
rhodamine 6G. In K. lactis, we have shown that an ABC
transporter, likely to be of the Pdr5-type, promotes the efflux of
rhodamine 6G in an energy-dependent and FK506-sensitive
manner. When sit4 mutants were examined, accumulation of
rhodamine 6G was indeed significantly decreased compared with wild-type
cells. As the strong rhodamine 6G efflux in sit4 cells is
sensitive to inhibition by the Pdr5-specific drug FK506, we can
conclude that the function of a Pdr5-type pump is up-regulated. These
results are in accord with the elevated resistance of sit4 mutants to the antifungal drugs ketoconazole and econazole, which share
the same transporter with rhodamine 6G in S. cerevisiae. Another line of evidence supporting the involvement of Sit4p in regulating expression/activity of membrane ABC transporters is our
preliminary study showing altered protein levels of ABC transporters in
sit4 mutants. Immunoblot analysis using antibodies against S. cerevisiae proteins has revealed that the accumulation of
Pdr12- and Snq2-like transporters in K. lactis is in fact
decreased by severalfold in sit4 cells,4 which
is in agreement with the down-regulation pattern of resistance for
sorbic acid and 4-NQO in sit4 mutants.
As discussed above, the Sit4 phosphatase is involved in the regulation
of different types of membrane transporters in both a positive and a
negative manner. Mechanistically, control by the Sit4 phosphatase can
intervene at different levels as follows: 1) Sit4p could modulate the
function of the transcriptional factors that activate expression of
particular ABC transporter genes; 2) Sit4p may control membrane
targeting and turnover of the drug transporters; and 3) Sit4p could
also directly regulate the drug pumping activity or substrate
specificity of the membrane transporters by dephosphorylating a
phospho-Ser/Thr residue(s). In S. cerevisiae, although most
multidrug-resistant mutants are confined to mutations in
transcriptional factors, some ABC transporters such as Pdr5 are
ubiquitinated (82) and subjected to vacuolar degradation (83). It has
also been documented that phosphorylation in a hypothetical modular
domain of the yeast Ycf1 transporter is important for drug resistance
(21). Each type of ABC transporter may thus adopt a different
regulatory pattern. In K. lactis, because both positive and
negative regulation are observed in sit4 mutants, it can be
imagined that more than one pathway operates to achieve the regulation
of individual transporters by Sit4p. Elucidation of the regulatory
mechanisms would first require the isolation and characterization of
K. lactis ABC transporter genes, which is currently underway
in our laboratories.
 |
ACKNOWLEDGEMENTS |
We thank Naomi Degabriele for helping with
the cloning of KlSIT4; K. Arndt (Cold Spring Harbor
Laboratory) for providing S. cerevisiae sit4 mutants and the
ScSIT4 gene; M. J. R. Stark (University of Dundee) for
phylogenetic analysis of KlSIT4; L.-J. Ouyang and H. Liszczynsky for technical assistance; and M. Muehlbauer for advice and
help with fluorescence-activated cell sorter analysis. The generous
gift of FK506 by Fujisawa Inc. is highly appreciated.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
The nucleotide sequence(s) reported in this paper has been submitted to the GenBankTM/EMBL Data Bank with accession number(s) X87624.
§
To whom correspondence should be addressed: Molecular Genetics and
Evolution Group, Research School of Biological Sciences, The Australian
National University, Biology Place, RSBS Bldg., GPO Box 475, Canberra
City, ACT 2601, Australia. Tel.: 61 2 6249 4510; Fax: 61 2 6279 8294;
E-mail: chen@rsbs.anu.edu.au.
Supported by Fonds zur Förderung der Wissenschaftlichen
Forschung (FWF, P12261-BIO).
2
X. J. Chen, unpublished observations.
3
M. J. R. Stark, personal communication.
4
X. J. Chen, B. E. Bauer, K. Kuchler,
and G. D. Clark-Walker, unpublished observations.
5
G. D. Clark-Walker, unpublished data.
 |
ABBREVIATIONS |
The abbreviations used are:
MDR, multidrug
resistance;
ABC transporter, ATP-binding cassette transporter;
GlyYP, complete glycerol medium;
GMM, minimal glucose medium;
GYP, complete
glucose medium;
4-NQO, 4-nitroquinoline-N-oxide;
PBS, phosphate-buffered saline;
P-gp, P-glycoprotein.
 |
REFERENCES |
| 1.
|
Simon, S. M.,
and Schindler, M.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
3497-3504[Abstract/Free Full Text]
|
| 2.
|
Cole, S. P.,
and Deeley, R. G.
(1998)
BioEssays
20,
931-940[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Gottesman, M. M.,
Hrycyna, C. A.,
Schoenlein, P. V.,
Germann, U. A.,
and Pastan, I.
(1995)
Annu. Rev. Genet.
29,
607-649[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Higgins, C. F.
(1992)
Annu. Rev. Cell Biol.
8,
67-113[CrossRef]
|
| 5.
|
Cowman, A. F.,
and Foote, S. J.
(1990)
Int. J. Parasitol.
20,
503-513[CrossRef][Medline]
[Order article via Infotrieve]
|
| 6.
|
Foote, S. J.,
Thompson, J. K.,
Cowman, A. F.,
and Kemp, D. J.
(1989)
Cell
57,
921-930[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Prasad, R.,
De Wergifosse, P.,
Goffeau, A.,
and Balzi, E.
(1995)
Curr. Genet.
27,
320-329[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Sanglard, D.,
Kuchler, K.,
Ischer, F.,
Pagani, J. L.,
Monod, M.,
and Bille, J.
(1995)
Antimicrob. Agents Chemother.
39,
2378-2386[Abstract]
|
| 9.
|
Van Veen, H. W.,
Callaghan, R.,
Soceneantu, L.,
Sardini, A.,
Konings, W. N.,
and Higgins, C. F.
(1998)
Nature
291,
291-295
|
| 10.
|
Decottignies, A.,
and Goffeau, A.
(1997)
Nat. Genet.
15,
137-145[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Kolaczkowski, M.,
Kolaczowska, A.,
Luczynski, J.,
Witek, S.,
and Goffeau, A.
(1998)
Microb. Drug Resist.
4,
143-158[Medline]
[Order article via Infotrieve]
|
| 12.
|
Kolaczkowski, M.,
van der Rest, M.,
Cybularz-Kolaczkowska, A.,
Soumillion, J. P.,
Konings, W. N.,
and Goffeau, A.
(1996)
J. Biol. Chem.
271,
31543-31548[Abstract/Free Full Text]
|
| 13.
|
Balzi, E.,
Wang, M.,
Leterme, S.,
van Dyck, L.,
and Goffeau, A.
(1994)
J. Biol. Chem.
269,
2206-2214[Abstract/Free Full Text]
|
| 14.
|
Bissinger, P. H.,
and Kuchler, K.
(1994)
J. Biol. Chem.
269,
4180-4186[Abstract/Free Full Text]
|
| 15.
|
Cui, Z.,
Hirata, D.,
Tsuchiya, E.,
Osada, H.,
and Miyakawa, T.
(1996)
J. Biol. Chem.
271,
14712-147126[Abstract/Free Full Text]
|
| 16.
|
Hirata, D.,
Yano, K.,
Miyahara, K.,
and Miyakawa, T.
(1994)
Curr. Genet.
26,
285-294[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Katzmann, D. J.,
Hallström, T. C.,
Voet, M.,
Wysock, W.,
Golin, J.,
Volckaert, G.,
and Moye-Rowley, W. S.
(1995)
Mol. Cell. Biol.
15,
6875-6883[Abstract]
|
| 18.
|
Li, Z. S.,
Szczypka, M.,
Lu, Y. P.,
Thiele, D. J.,
and Rea, P. A.
(1996)
J. Biol. Chem.
271,
6509-6517[Abstract/Free Full Text]
|
| 19.
|
Rebbeor, J. F.,
Connolly, G. C.,
Dumont, M. E.,
and Ballatori, N.
(1998)
J. Biol. Chem.
273,
33449-33454[Abstract/Free Full Text]
|
| 20.
|
Servos, J.,
Haase, E.,
and Brendel, M.
(1993)
Mol. Gen. Genet.
236,
214-218[CrossRef][Medline]
[Order article via Infotrieve]
|
| 21.
|
Szczpka, M. S.,
Wemmie, J. A.,
Moye-Rowley, W. S.,
and Thiele, D. J.
(1994)
J. Biol. Chem.
269,
22853-22857[Abstract/Free Full Text]
|
| 22.
|
Wemmie, J. A.,
Szczypka, M. S.,
Thiele, D. J.,
and Moye-Rowley, W. S.
(1994)
J. Biol. Chem.
269,
32592-32597[Abstract/Free Full Text]
|
| 23.
|
Kuchler, K.,
and Thorner, J.
(1992)
Proc. Natl. Acad. Sci. U. S. A.
89,
2302-2306[Abstract/Free Full Text]
|
| 24.
|
Raymond, M.,
Ruetz, S.,
Thomas, D. Y.,
and Gros, P.
(1994)
Mol. Cell. Biol.
14,
277-286[Abstract/Free Full Text]
|
| 25.
|
Ruetz, S.,
Brault, M.,
Kast, C.,
Hemenway, C.,
Heitman, J.,
Grant, C. E.,
Cole, S. P.,
Deeley, R. G.,
and Gros, P.
(1996)
J. Biol. Chem.
271,
4154-4160[Abstract/Free Full Text]
|
| 26.
|
Tommasini, R.,
Evers, R.,
Vogt, E.,
Mornet, C.,
Zaman, G. J.,
Achinkel, A. H.,
Borst, P.,
and Martinoia, E.
(1996)
Proc. Natl. Acad. Sci. U. S. A.
93,
6743-6748[Abstract/Free Full Text]
|
| 27.
|
Ueda, K.,
Shimabuku, A. M.,
Konishi, H.,
Fujii, Y.,
Takebe, S.,
Nishi, K.,
Yoshida, M.,
Beppu, T.,
and Komano, T.
(1993)
FEBS Lett.
330,
179-282
|
| 28.
|
Balzi, E.,
Chen, W.,
Ulaszewski, S.,
Capieaux, E.,
and Goffeau, A.
(1987)
J. Biol. Chem.
262,
16871-16879[Abstract/Free Full Text]
|
| 29.
|
Cui, Z.,
Shiraki, T.,
Hirata, D.,
and Miyakawa, T.
(1998)
Mol. Microbiol.
29,
1307-1315[CrossRef][Medline]
[Order article via Infotrieve]
|
| 30.
|
Delaveau, T.,
Delahodde, A.,
Carvajal, E.,
Subik, J.,
and Jacq, C.
(1994)
Mol. Gen. Genet.
244,
501-511[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Dexter, D.,
Moye-Rowley, W. S.,
Wu, A.-L.,
and Golin, J.
(1994)
Genetics
136,
505-515[Abstract]
|
| 32.
|
Subik, J.,
Ulaszewki, S.,
and Goffeau, A.
(1986)
Curr. Genet.
10,
665-670[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Decottignies, A.,
Lambert, L.,
Catty, P.,
Degand, H.,
Epping, E. A.,
Moye-Rowley, W. S.,
Balzi, E.,
and Goffeau, A.
(1995)
J. Biol. Chem.
270,
18150-18157[Abstract/Free Full Text]
|
| 34.
|
Hallström, T. C.,
and Moye-Rowley, W. S.
(1998)
J. Biol. Chem.
273,
2098-2104[Abstract/Free Full Text]
|
| 35.
|
Katzmann, D. J.,
Burnett, P. E.,
Golin, J.,
Mahé, Y.,
and Moye-Rowley, W. S.
(1994)
Mol. Cell. Biol.
14,
4653-4661[Abstract/Free Full Text]
|
| 36.
|
Mahé, Y.,
Parle-McDermott, A.,
Delahodde, A.,
Lamprecht, A.,
and Kuchler, K.
(1996)
Mol. Microbiol.
20,
109-117[Medline]
[Order article via Infotrieve]
|
| 37.
|
Meyers, S.,
Schauer, W.,
Balzi, E.,
Wagner, M.,
Goffeau, A.,
and Golin, J.
(1992)
Curr. Genet.
21,
431-436[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Hallström, T. C.,
Katzmann, D. J.,
Torres, R. J.,
Sharp, W. J.,
and Moye-Rowley, W. S.
(1998)
Mol. Cell. Biol.
18,
1147-1155[Abstract/Free Full Text]
|
| 39.
|
Wendler, F.,
Bergler, H.,
Prutej, K.,
Jungwirth, H.,
Zisser, G.,
Kuchler, K.,
and Högenauer, G.
(1997)
J. Biol. Chem.
272,
27091-27098[Abstract/Free Full Text]
|
| 40.
|
Center, M. S.
(1983)
Biochem. Biophys. Res. Commun.
115,
159-166[CrossRef][Medline]
[Order article via Infotrieve]
|
| 41.
|
Hamada, H.,
Hagiwara, K. I.,
Nakajima, T.,
and Tsuruo, T.
(1987)
Cancer Res.
47,
2860-2865[Abstract/Free Full Text]
|
| 42.
|
Gekeler, V.,
Boer, R.,
Ise, W.,
Sanders, K. H.,
Schachtele, C.,
and Beck, J.
(1995)
Biochem. Biophys. Res. Commun.
206,
119-126[CrossRef][Medline]
[Order article via Infotrieve]
|
| 43.
|
Ma, L.-D.,
Krishnamachary, N.,
and Center, M. S.
(1995)
Biochemistry
34,
3338-3343[CrossRef][Medline]
[Order article via Infotrieve]
|
| 44.
|
Germann, U. A.,
Chambers, T. C.,
Ambudkar, S. V.,
Licht, T.,
Cardarelli, C. O.,
Pastan, I.,
and Gottesman, M. M.
(1996)
J. Biol. Chem.
271,
1708-1716[Abstract/Free Full Text]
|
| 45.
|
Goodfellow, H. R.,
Sardini, A.,
Ruetz, S.,
Callaghan, R.,
Gros, P.,
McNaughton, P. A.,
and Higgins, C. F.
(1996)
J. Biol. Chem.
271,
13668-13674[Abstract/Free Full Text]
|
| 46.
|
Glavy, J. S.,
Horwitz, S. B.,
and Orr, G. A.
(1997)
J. Biol. Chem.
272,
5909-5914[Abstract/Free Full Text]
|
| 47.
|
Piper, P.,
Mahé, Y.,
Thompson, S.,
Pandjaitan, R.,
Holyoak, C.,
Egner, R.,
Mühlbauer, M.,
Coote, P.,
and Kuchler, K.
(1998)
EMBO J.
17,
4257-4265[CrossRef][Medline]
[Order article via Infotrieve]
|
| 48.
|
Giezt, D.,
Jean, A. S.,
Wood, R. A.,
and Schiestl, R. H.
(1992)
Nucleic Acids Res.
20,
1425[Free Full Text]
|
| 49.
|
Chen, X. J.,
and Clark-Walker, G. D.
(1994)
Mol. Cell. Biol.
14,
4501-4508[Abstract/Free Full Text]
|
| 50.
|
Sherman, F.,
Fink, G. R.,
and Hicks, J. B.
(1983)
Methods in Yeast Genetics
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 51.
|
Sambrook, J.,
Fritsch, E. F.,
and Maniatis, T.
(1989)
Molecular Cloning: A Laboratory Manual
, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY
|
| 52.
|
Chen, X. J.,
and Fukuhara, H.
(1988)
Gene (Amst.)
69,
181-192[CrossRef][Medline]
[Order article via Infotrieve]
|
| 53.
|
Chen, X. J.
(1996)
Gene (Amst.)
172,
131-136[CrossRef][Medline]
[Order article via Infotrieve]
|
| 54.
|
Bonneaud, N.,
Ozier-Kalogeropoulos, O.,
Li, G.,
Labouesse, M.,
Minvielle-Sebastia, L.,
and Lacroute, F.
(1991)
Yeast
7,
609-615[CrossRef][Medline]
[Order article via Infotrieve]
|
| 55.
|
Wésolowski-Louvel, M.,
Tanguy-Rougeau, C.,
and Fukuhara, H.
(1986)
Yeast
4,
71-81
|
| 56.
|
Sanger, F. S.,
Nicklen, S.,
and Coulson, A. R.
(1977)
Proc. Natl. Acad. Sci. U. S. A.
74,
5463-5467[Abstract/Free Full Text]
|
| 57.
|
Rothstein, R. J.
(1983)
Methods Enzymol.
101,
202-210[Medline]
[Order article via Infotrieve]
|
| 58.
|
Chen, X. J.,
and Clark-Walker, G. D.
(1995)
EMBO J.
14,
3277-3286[Medline]
[Order article via Infotrieve]
|
| 59.
|
Law, R. H. B.,
Manon, S.,
Devenish, R. J.,
and Nagley, P.
(1995)
Methods Enzymol.
260,
133-163[Medline]
[Order article via Infotrieve]
|
| 60.
|
Chen, X. J.,
and Clark-Walker, G. D.
(1993)
Genetics
133,
517-525[Abstract]
|
| 61.
|
Chen, X. J.,
and Clark-Walker, G. D.
(1996)
Genetics
144,
1445-1454[Abstract]
|
| 62.
|
Avner, P. R.,
and Griffiths, D. E.
(1973)
Eur. J. Biochem.
15,
312-321
|
| 63.
|
Brunner, A.,
de Cobos, A. T.,
and Griffiths, D. E.
(1977)
Mol. Gen. Genet.
152,
183-191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 64.
|
Ooi, G. G.,
Novitski, C. E.,
and Nagley, P.
(1985)
Eur. J. Biochem.
152,
709-714[Medline]
[Order article via Infotrieve]
|
| 65.
|
Ray, M. K.,
Connerton, I. F.,
and Griffiths, D. E.
(1988)
Biochim. Biophys. Acta
951,
213-219[Medline]
[Order article via Infotrieve]
|
| 66.
|
Arndt, K. T.,
Styles, C. A.,
and Fink, G. R.
(1989)
Cell
56,
527-537[CrossRef][Medline]
[Order article via Infotrieve]
|
| 67.
|
Matsumoto, T.,
and Beach, D.
(1993)
Mol. Biol. Cell
4,
337-345[Abstract]
|
| 68.
|
Sazer, S.,
and Nurse, P.
(1994)
EMBO J.
13,
606-615[Medline]
[Order article via Infotrieve]
|
| 69.
|
Shimanuki, M.,
Kinoshita, N.,
Ohkura, H.,
Yoshida, T.,
Toda, T.,
and Yanagida, M.
(1993)
Mol. Biol. Cell
4,
303-313[Abstract]
|
| 70.
|
Mann, D. J.,
Dombrádi, V.,
and Cohen, P. T. W.
(1993)
EMBO J.
12,
4833-4842[Medline]
[Order article via Infotrieve]
|
| 71.
|
Bastians, H.,
and Ponstingl, H.
(1996)
J. Cell Sci.
109,
2865-2874[Abstract]
|
| 72.
|
Sutton, A.,
Immanuel, D.,
and Arndt, K. T.
(1991)
Mol. Cell. Biol.
11,
2133-2148[Abstract/Free Full Text]
|
| 73.
|
Egner, R.,
Rosenthal, F. E.,
Kralli, A.,
Sanglard, D.,
and Kuchler, K.
(1998)
Mol. Biol. Cell
9,
523-543[Abstract/Free Full Text]
|
| 74.
|
Kralli, A.,
and Yamamoto, K. R.
(1996)
J. Biol. Chem.
271,
17152-17156[Abstract/Free Full Text]
|
| 75.
|
Stark, M. J. R.,
Black, S.,
Sneddon, A. A.,
and Andrews, P. D.
(1994)
FEMS Microbiol. Lett.
117,
121-130[CrossRef][Medline]
[Order article via Infotrieve]
|
| 76.
|
Fernandez-Sarabia, M. J.,
Sutton, A.,
Zhong, T.,
and Arndt, K. T.
(1992)
Genes Dev.
6,
2417-2428[Abstract/Free Full Text]
|
| 77.
|
Posas, F.,
Clotet, J.,
and Arino, J.
(1991)
FEBS Lett.
279,
341-345[CrossRef][Medline]
[Order article via Infotrieve]
|
| 78.
|
Nickels, J. T.,
and Broach, J. R.
(1996)
Genes Dev.
10,
382-394[Abstract/Free Full Text]
|
| 79.
|
Di Como, C. J.,
and Arndt, K. T.
(1996)
Genes Dev.
10,
1904-1916[Abstract/Free Full Text]
|
| 80.
|
Jiang, Y.,
and Broach, J. R.
(1999)
EMBO J.
18,
2782-2792[CrossRef][Medline]
[Order article via Infotrieve]
|
| 81.
|
Wolfger, H.,
Mahé, Y.,
Parle-McDermott, A.,
Delahodde, A.,
and Kuchler, K.
(1997)
FEBS Lett.
418,
269-274[CrossRef][Medline]
[Order article via Infotrieve]
|
| 82.
|
Egner, R.,
and Kuchler, K.
(1996)
FEBS Lett.
378,
177-181[CrossRef][Medline]
[Order article via Infotrieve]
|
| 83.
|
Egner, R.,
Mahé, Y.,
Pandjaitan, R.,
and Kuchler, K.
(1995)
Mol. Cell. Biol.
15,
5879-5887[Abstract]
|
| 84.
|
Chen, X. J.,
Wésolowski-Louvel, M.,
and Fukuhara, H.
(1992)
Mol. Gen. Genet.
233,
97-105[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2000 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
X. J. Chen
Activity of the Kluyveromyces lactis Pdr5 Multidrug Transporter Is Modulated by the Sit4 Protein Phosphatase
J. Bacteriol.,
July 1, 2001;
183(13):
3939 - 3948.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. A. Masuda, J. Ramirez, A. Pena, and M. Montero-Lomeli
Regulation of Monovalent Ion Homeostasis and pH by the Ser-Thr Protein Phosphatase SIT4 in Saccharomyces cerevisiae
J. Biol. Chem.,
September 29, 2000;
275(40):
30957 - 30961.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2000 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|